Beigene Ltd
ONC337.890USD
+17.520+5.47%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
34.39BMarket Cap
549.39P/E TTM
More Details of Beigene Ltd Company
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltd Info
Ticker SymbolONC
Company nameBeOne Medicines AG
IPO dateMar 02, 2016
CEOOyler (John Victor)
Number of employees11000
Security typeDepository Receipt
Fiscal year-endMar 02
Addressc/o BeOne Medicines I GmbH
CityBASEL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code4051
Phone41616851900
Websitehttps://beonemedicines.com/
Ticker SymbolONC
IPO dateMar 02, 2016
CEOOyler (John Victor)
Company Executives of Beigene Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
Other
-1.31B
-92.66%
By RegionUSD
Name
Revenue
Proportion
United States
754.86M
53.45%
China
439.88M
31.15%
Europe
166.58M
11.79%
ROW
50.97M
3.61%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
Other
-1.31B
-92.66%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
Other
62.04%
Shareholders
Shareholders
Proportion
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
Other
62.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.53%
Corporation
17.28%
Hedge Fund
8.21%
Investment Advisor/Hedge Fund
3.74%
Sovereign Wealth Fund
0.92%
Research Firm
0.57%
Pension Fund
0.03%
Family Office
0.02%
Family Office
0.02%
Other
51.66%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
564
34.03M
31.03%
-4.53M
2025Q3
565
40.04M
36.51%
-2.11M
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Amgen Inc
18.94M
17.27%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.02%
--
--
Sep 30, 2025
PRIMECAP Management Company
5.08M
4.63%
-7.82K
-0.15%
Sep 30, 2025
Capital International Investors
5.05M
4.6%
+161.05K
+3.30%
Sep 30, 2025
Fidelity Management & Research Company LLC
3.76M
3.43%
+345.36K
+10.12%
Sep 30, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
Sep 30, 2025
Temasek Holdings Pte. Ltd.
1.01M
0.92%
+999.00
+0.10%
Sep 30, 2025
T. Rowe Price International Ltd
941.86K
0.86%
+9.96K
+1.07%
Sep 30, 2025
T. Rowe Price Associates, Inc.
688.71K
0.63%
+600.48K
+680.59%
Sep 30, 2025
Invus Public Equities Advisors, LLC
492.99K
0.45%
-17.00K
-3.33%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Biotech ETF
4.03%
First Trust NYSE Arca Biotechnology Index Fund
3.26%
Tema Oncology ETF
2.65%
Global X Aging Population ETF
2.41%
Virtus LifeSci Biotech Products ETF
1.8%
iShares Biotechnology ETF
1.71%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.02%
National Security Emerging Markets Index ETF
0.83%
Capital Group Global Equity ETF
0.79%
View more
VanEck Biotech ETF
Proportion4.03%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.26%
Tema Oncology ETF
Proportion2.65%
Global X Aging Population ETF
Proportion2.41%
Virtus LifeSci Biotech Products ETF
Proportion1.8%
iShares Biotechnology ETF
Proportion1.71%
ProShares Ultra Nasdaq Biotechnology
Proportion1.02%
Invesco Nasdaq Biotechnology ETF
Proportion1.02%
National Security Emerging Markets Index ETF
Proportion0.83%
Capital Group Global Equity ETF
Proportion0.79%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Beigene Ltd?
The top five shareholders of Beigene Ltd are:
Amgen Inc holds 18.94M shares, accounting for 17.27% of the total shares.
Baker Bros. Advisors LP holds 8.80M shares, accounting for 8.02% of the total shares.
PRIMECAP Management Company holds 5.08M shares, accounting for 4.63% of the total shares.
Capital International Investors holds 5.05M shares, accounting for 4.60% of the total shares.
Fidelity Management & Research Company LLC holds 3.76M shares, accounting for 3.43% of the total shares.
Amgen Inc holds 18.94M shares, accounting for 17.27% of the total shares.
Baker Bros. Advisors LP holds 8.80M shares, accounting for 8.02% of the total shares.
PRIMECAP Management Company holds 5.08M shares, accounting for 4.63% of the total shares.
Capital International Investors holds 5.05M shares, accounting for 4.60% of the total shares.
Fidelity Management & Research Company LLC holds 3.76M shares, accounting for 3.43% of the total shares.
What are the top three shareholder types of Beigene Ltd?
The top three shareholder types of Beigene Ltd are:
Amgen Inc
Baker Bros. Advisors LP
PRIMECAP Management Company
Amgen Inc
Baker Bros. Advisors LP
PRIMECAP Management Company
How many institutions hold shares of Beigene Ltd (ONC)?
As of 2025Q4, 564 institutions hold shares of Beigene Ltd, with a combined market value of approximately 34.03M, accounting for 31.03% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -5.48%.
What is the biggest source of revenue for Beigene Ltd?
In FY2025Q3, the Product business generated the highest revenue for Beigene Ltd, amounting to 1.37B and accounting for 97.35% of total revenue.
